Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine

Transplantation

Volumn 51, Issue 3, 1991, Pages 701-705

  Garcia Maldonado, Maurilio ^a   Kaufman, Christian E ^a   Comp, Philip C ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; THROMBOMODULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RISK FACTOR; THROMBOSIS;

ANIMAL; AORTA; CATTLE; CELLS, CULTURED; CYCLOSPORINS; ENDOTHELIUM, VASCULAR; KINETICS; MODELS, CARDIOVASCULAR; PROTEIN C; RECEPTORS, CELL SURFACE; RECEPTORS, THROMBIN; RENAL ARTERY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBIN; THROMBOSIS;

EID: 0025729516     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199103000-00030     Document Type: Article

References (55)

1. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984; 101: 667.
2. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725
3. The Canadian Multicentre Transplant Study Group. A randomized trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809.
4. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: one year follow up of a multicentre trial. Lancet 1983; 1: 989.
5. Shulman H, Striker G, Deeg HJ, Kennedy M, Strob R, Thomas ED. Nephrotoxicity of cyclosporine A after allogenic marrow transplantation: glomerular thrombosis and tubular injury. N Engl J Med 1981; 305: 1392.
6. Neild GH, Reuben R, Hartley RB, Cameron JS. Glomerular thrombi in renal allografts associated with cyclosporine treatment. J Clin Pathol 1985; 38: 253.
7. Chouhury M, Neild GH, Brown Z, Cameron JS. Thromboembolic complications in cyclosporine treated kidney allograft recipients. Lancet 1985; 2: 606.
8. Schlanger RE, Henry ML, Sommer BG, Ferguson RM. Identification and treatment of cyclosporine-associated allograft thrombosis. Surgery 1986; 100: 329.
9. Samara ENS, Voss BL, Pederson JA. Renal artery thrombosis associated with elevated cyclosporine levels: a case report and review of the literature. Transplant Proc 1988; 20: 119.
10. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30: 964.
11. Vanrentergham Y, Roels T, Lerut T, Grutwez J, Michielsen P. Thromboembolic complications and hemostatic changes in cyclosporine-treated cadaveric kidney allograft recipients. Lancet 1985; 1: 999.
12. Allen RD, Michie CA, Morris PJ, Chapman JR. Venous thrombosis and cyclosporin. Lancet 1985; 2: 1004.
13. Brunkwall J, Bergqvist D, Bergentz SE, Bronmyr S, Husberg B. Postoperative deep thrombosis after renal transplantation: effects of cyclosporine. Transplantation 1987; 43: 647.
14. Comp PC. Natural anticoagulants: protein C, protein S, and antithrombin III. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology. 4th ed. San Francisco: McGraw-Hill. 1990: 1776.
15. Esmon NL. Thrombomodulin. Semin Thromb Hemost 1987; 13: 454.
16. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743.
17. Comp PC. Hereditary disorders predisposing to thrombosis. Prog Hemost Thromb 1986; 8: 71.
18. Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314: 1298.
19. Marcum JA, Rosenberg JS, Bauer KA, Rosenberg RD. The heparin-antithrombin mechanism and vessel wall function. In: Gim- brone MA Jr, ed. New York: Churchill Livingstone, 1986: 70.
20. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249.
21. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibit both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257: 7944.
22. Susuki K, Stenflo J, Dahlback B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 1914.
23. Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258: 12238.
24. Walker FJ. Regulation of activated protein C by a new protein a possible function for protein S. J Biol Chem 1980; 255: 5521.
25. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated protein C and its analogy to factor V. Blood 1989; 255: 486.
26. Brown Z, Neild GH, Willoughby JJ, Somia NV, Cameron JS. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 1986; 42: 150.
27. Lau DC, Wong KL. Effect of cyclosporine on microvascular endothelial cell growth in culture. Transplant Proc 1987; 19: 3496.
28. Lau CW, Wong KL, Hwang WS. Cyclosporine toxicity on culturedrat microvascular endothelial cells. Kidney Int 1989; 35: 604.
29. Trifillis AL, Hall-Craggs M. Effects of cyclosporine on human endothelial cell cultures. Toxicol Pathol 1986; 14: 210.
30. Zoja C, Furci L, Ghilardi F, Zilio P. Cyclosporine-induced endothelial cell injury. Lab Invest 1986; 55: 455.
31. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979; 571: 333.
32. Stern DM, Bank I, Nawroth PP, et al. Self regulation of procoagulant events on the endothelial surface. J Exp Med 1985; 162: 1223.
33. Jaffe EA. Endothelial cells and the biology of factor VIII. N Engl J Med 1977; 296: 377.
34. Esmon NL, DeBault LE, Esmon CT. Proteolytic formation and properties of gamma-carboxy-glutamic acid-domainless protein C. J Biol Chem 1983; 258: 5548.
35. Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, Wood A. Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 1983; 34: 638.
36. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107.
37. Neild GH, Reuben R, Hartley RB, Cameron JS. Glomerular thrombi in renal allografts associated with cyclosporine treatment. J Clin Pathol 1985; 38: 253.
38. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348.
39. Jakubowsky HV, Kline MD, Owen WG. The effect of bovine thrombomodulin on the specificity of bovine thrombin. J Biol Chem 1986; 261: 3876.
40. Sommer BG, Innes JT, Whitehurst RM, Sharma HM, Ferguson RM. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg 1985; 149: 756.
41. Stork JE, Rahman MA, Dunn MJ. Eicosanoids in experimental and human renal disease. Am J Med 1986; 80 (suppl 1A): 34.
42. Honis JM, Chipping PM, Fairhead S, Smith J. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A. Br J Haematol 1983; 54: 69.
43. Atkinson K, Briggs JC, Hayes J, Ralston M, Dodds AJ. Cyclosporin A associated nephropathy in the first 100 days after allogenic bone marrow transplantation: three distinct syndromes. Br J Haematol 1983; 54: 59.
44. Neild GH, Ivory K, Williams DG. Glomerular thrombosis and cortical infarction in cyclosporin treated rabbits with acute serum sickness. Br J Exp Pathol 1984; 65: 133.
45. Voss BL, Hamilton KK, Samara ENS, McKee PA. Cyclosporine suppression of endothelial protacyclin generation: a possible mechanism for nephrotoxicity. Transplantation 1988; 4: 793.
46. Neild GH, Rocchi G, Imberti L, et al. Effect of cyclosporine A on prostacyclin synthesis by vascular tissue. Thromb Res 1983; 32: 373.
47. Mikhailidis DP, Barradas MA, Maris A, Jeremy JY. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release. J Clin Pathol 1985; 38: 1166.
48. Grace AA, Barradas MA, Mikhailidis DP, Jeremy JY, Moorhead JF, Dandona P. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32: 889.
49. Carlsen E, Flatmark A, Prydz H. Cyclosporine as a biologic response modifier in the regulation of monocyte and endothelial cell procoagulant synthesis. Transplant Proc 1988; 20: 528.
50. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767.
51. Jackson NM, Hsu C-H, Visscher GE, Venkatalachalam MA, Humes HD. Alterations in renal vasculature and function in a rat model of cyclosporine nephrotoxicity. J Pharmacol Exp Ther 1987; 242: 749.
52. Meyer-Lehnert H, Schrier RW. Cyclosporine A enhances vasopressin-induced calcium mobilization and contraction in mesangial cells. Kidney Int 1987; 34: 89.
53. Holt DW, Mardsen JT, Johnston A, Bewick M, Taube DH. Blood cyclosporine concentrations and renal allograft dysfunction. Br Med J 1986; 293: 1057.
54. Moyer T, Post CR, Sterioff S, Anderson CF. Cyclosporine nephrotoxicity is minimized by adjusting the dose of the basis of drug concentration in blood. Mayo Clin Proc 1988; 63: 241.
55. Bauer KA, Broekmans AW, Bertina RM, et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. J Clin Invest 1988; 71: 1418.